Moderna posts bigger loss than expected
Julie Hyman and Josh Lipton preview the biggest earnings stories and economic data due out tomorrow, Friday, February 14. Pharmaceutical company Moderna (MRNA) and energy provider Enbridge (ENB) are ...
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
1d
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...
Inflation data, Powell testimony, more earnings will be in focus this week. • Robinhood’s strong financial health, robust ...
Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.
Moderna is down 80% from its 52-week high as ... including up to three potential 2025 approvals and six registrational data readouts. MRNA comments, January 13, 2025, press release.
Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback